uniQure N.V.
Research uniQure N.V. (QURE) on Bullrun: market cap USD 3.54B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerQURE
- ExchangeNASDAQ
- CountryNetherlands
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.54B
- Financial periodQ2 2026
- RevenueUSD 5.84M
- Net income-USD 81.06M
- Free cash flow-USD 29.05M
- Gross margin94.0%
Valuation Snapshot
latest market cap is USD 3.54B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 16.10M | -USD 199.00M | -USD 178.40M | 89.5% | -3.46 | USD 80.24M | USD 49.70M | USD 198.90M |
| FY2024 | USD 27.12M | -USD 239.60M | -USD 186.10M | 95.3% | -4.92 | USD 158.93M | USD 51.32M | -USD 6.75M |
| FY2023 | USD 15.84M | -USD 308.50M | -USD 153.08M | 99.6% | -6.47 | USD 241.36M | USD 101.75M | USD 207.67M |
| FY2022 | USD 106.48M | -USD 126.80M | -USD 162.75M | 98.8% | -2.71 | USD 228.01M | USD 102.79M | USD 476.01M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.54B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.50B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 865.13M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 323.68M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.06B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 960.23M | 3.0 | n/a | n/a |
About uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is uniQure N.V.'s market cap?
uniQure N.V.'s market capitalization is USD 3.54B.
What does uniQure N.V. do?
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease.